{"id":89033,"date":"2025-01-09T10:30:09","date_gmt":"2025-01-09T10:30:09","guid":{"rendered":"https:\/\/pakistaninewspaperlist.com\/news\/rq-bio-welcomes-positive-chmp-opinion-on-kavigale-for-prevention-of-covid-19-in-immunocompromised-individuals\/"},"modified":"2025-01-09T10:30:09","modified_gmt":"2025-01-09T10:30:09","slug":"rq-bio-welcomes-positive-chmp-opinion-on-kavigale-for-prevention-of-covid-19-in-immunocompromised-individuals","status":"publish","type":"post","link":"https:\/\/pakistaninewspaperlist.com\/news\/rq-bio-welcomes-positive-chmp-opinion-on-kavigale-for-prevention-of-covid-19-in-immunocompromised-individuals\/","title":{"rendered":"RQ Bio welcomes positive CHMP opinion on Kavigale for prevention of COVID-19 in immunocompromised individuals"},"content":{"rendered":"<div id=\"main-body-container\" itemprop=\"articleBody\">\n<p align=\"center\"><b>RQ Bio welcomes positive CHMP opinion on Kavigale for prevention of COVID-19 in immunocompromised individuals<\/b><\/p>\n<ul type=\"disc\">\n<li>Kavigale (sipavibart; AZD3152) is a monoclonal antibody discovered by RQ Bio and licensed to AstraZeneca in 2022.<\/li>\n<li>Advancing from discovery to positive CHMP opinion in three years illustrates the speed with which long-acting monoclonal antibodies can be developed as a drug class to protect vulnerable populations against serious viral diseases.<\/li>\n<li>Further validates RQ Bio\u2019s antiviral drug discovery expertise and model for early partnership with the pharmaceutical industry.<\/li>\n<\/ul>\n<p align=\"justify\">London, England, 09 January 2025 \u2013 RQ Biotechnology Ltd. (\u201cRQ Bio\u201d), a leader in the discovery of preventative medicines for infectious diseases, today welcomes the decision by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) to recommend the granting of marketing authorisation for the medicinal product Kavigale. Kavigale is intended for the prevention of COVID-19 in immunocompromised individuals- aged 12 years and older and was reviewed under the EMA\u2019s accelerated assessment programme.<\/p>\n<p align=\"justify\">\u201cThis welcome news is further validation of our expertise in antiviral drug discovery and our model for early partnership with the pharmaceutical industry to rapidly advance potentially important new medicines,\u201d RQ Bio CEO Mike Westby said. \u201cThe programme has transitioned from discovery to positive regulatory opinion in three years. This is truly remarkable and highlights the pace with which long-acting prophylactic antibodies can now advance through pre-clinical and clinical development.\u201d<\/p>\n<p align=\"justify\">The active substance of Kavigale is sipavibart, an antiviral human IgG1 monoclonal antibody discovered by RQ Bio in partnership with The University of Oxford. Sipavibart provides passive protection against SARS-CoV 2 by binding its spike protein receptor binding domain.<\/p>\n<p align=\"justify\">AstraZeneca exclusively licenced sipavibart (formerly AZD3152) from RQ Bio in May 2022.<\/p>\n<p align=\"justify\">Hayden Selvadurai, Head of Portfolio Management at RQ Bio, commented, \u201cThis positive opinion from the CHMP highlights the productive relationship we have with a trusted pharma partner. We\u2019re excited about the opportunity to build on this experience and are advancing assets from our other programmes, including seasonal influenza, to provide protection for vulnerable individuals that are unable to build an optimal immune response from vaccination.\u201d<\/p>\n<p align=\"justify\">ENDS<\/p>\n<p align=\"justify\"><b>Enquiries<\/b><br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=yFgCn5bRfxLpriPCcNLoSuwnn04ogDrxP0MUdF9eeZLQlO5rOCeM01TOh63i2545TCzmrNigR0yG4PY6SkBMolLB9FtrE5xP6BDjAZWMOdEBqgz7T7fD7o9UoovJZZmM\" rel=\"nofollow\" target=\"_blank\" title=\"media@rqbiotechnology.com\">media@rqbiotechnology.com<\/a><br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=aHkWokPv1x6cdKQR8cTyLC4BJ0QVA8XMUxB8ckbhBSqj4mCNP_cc8gVdzzf93yl6PFGIVkx5lKwg6czU2hnzP-BJtqG8BQghxs9JD3DZJkI=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>www.rqbiotechnology.com<\/u><\/a><br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=l2QqHrj-utucVercD3q5S4V3OdYDwy-aqNg9Hjh8PXpzFdqYSv0-mR4YmWCPy8ouoeKYiJW4r7jWeBEXiZ8x9TGzKzo7W9BUnayxLOrfAf6uV9H9g7LaADECCTWSIB4A\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>LinkedIn<\/u><\/a><\/p>\n<p align=\"justify\"><b>ABOUT KAVIGALE<\/b><br \/>Kavigale is indicated for the preexposure prophylaxis of COVID-19 in adults and adolescents 12\u00a0years of age and older, weighing at least 40 kg and who are immunocompromised due to a medical condition or receipt of immunosuppressive treatments.<\/p>\n<p align=\"justify\"><b>ABOUT RQ BIO<\/b><br \/>RQ Bio\u2019s mission is to develop preventative medicines to provide instant immunity and protect vulnerable people from life threatening viral diseases. RQ Bio has achieved this by combining expertise in virology and drug development with deep academic collaborations, including the University of Oxford, to create an innovative discovery platform delivering multiple sources of leads. RQ Bio was founded by scientific experts previously involved with the UK\u2019s COVID Antibody Taskforce, which worked to build a community of infectious disease experts focussed on the rapid delivery of highly potent neutralising antibodies to support the UK COVID-19 response. In April 2024, RQ Bio Covid Ltd was formed to manage RQ Bio\u2019s licensed COVID assets, including sipavibart.<\/p>\n<ul id=\"gnw_attachments_section-items\">\n<li>\n        <a target=\"_blank\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=jK2MZgPb8sukWO3JP_aLQzQ2H1OAxB2kFS0z5JZ3GxOXfBAKM7judFHkjoqRNKoTLc-PMr8ezuAT8NW35eWCR-fRfe-ZrjS4BHv2sKiI6Nkw1b2zMQ5nf4UizsgyEGFcQvksJ-vk2KfCsArBASXmQ6lIVEGDsSb-T8D9HBYr7Osazrvfr3wwaq2rn7bvqHRX\" title=\"RQ Bio CHMP Positive Opinion Final\" rel=\"nofollow\">RQ Bio CHMP Positive Opinion Final<\/a>\n      <\/li>\n<\/ul>\n<p>\n            <\/div>\n","protected":false},"excerpt":{"rendered":"<p>RQ Bio welcomes positive CHMP opinion on Kavigale for prevention of COVID-19 in immunocompromised individuals Kavigale (sipavibart; AZD3152) is a monoclonal antibody discovered by RQ Bio and licensed to AstraZeneca in 2022. Advancing from discovery to positive CHMP opinion in three years illustrates the speed with which long-acting monoclonal antibodies can be developed as a [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":89034,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"fifu_image_url":"https:\/\/ml-eu.globenewswire.com\/Resource\/Download\/9d023a7a-cf6d-4d5b-a861-ce75232d7b83","fifu_image_alt":"","footnotes":""},"categories":[208],"tags":[],"class_list":["post-89033","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-globenewswire"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/posts\/89033","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/comments?post=89033"}],"version-history":[{"count":0,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/posts\/89033\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/media\/89034"}],"wp:attachment":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/media?parent=89033"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/categories?post=89033"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/tags?post=89033"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}